Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.47 0.00% 0.00
INFI closed unchanged on Monday, May 20, 2019, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INFI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.68%
Oversold Stochastic Weakness -0.68%
Bullish Engulfing Bullish 1.38%
Lower Bollinger Band Walk Weakness 1.38%
Oversold Stochastic Weakness 1.38%

Older signals for INFI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Diseases Chemical Substances Drug Discovery Inflammation Non Small Cell Lung Cancer Rheumatoid Arthritis Hematologic Malignancies Phosphoinositide 3 Kinase Inhibitor Pyrimidines Allergic Asthma Nsclc
Is INFI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.92
52 Week Low 1.0
Average Volume 167,510
200-Day Moving Average 1.7393
50-Day Moving Average 1.6644
20-Day Moving Average 1.561
10-Day Moving Average 1.488
Average True Range 0.0872
ADX 16.91
+DI 16.5765
-DI 18.626
Chandelier Exit (Long, 3 ATRs ) 1.5162
Chandelier Exit (Short, 3 ATRs ) 1.6616
Upper Bollinger Band 1.7573
Lower Bollinger Band 1.3647
Percent B (%b) 0.27
BandWidth 25.150545
MACD Line -0.057
MACD Signal Line -0.0468
MACD Histogram -0.0103
Fundamentals Value
Market Cap 74.51 Million
Num Shares 50.7 Million
EPS -1.39
Price-to-Earnings (P/E) Ratio -1.06
Price-to-Sales 0.00
Price-to-Book 1.82
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.53
Resistance 3 (R3) 1.53 1.50 1.52
Resistance 2 (R2) 1.50 1.49 1.50 1.52
Resistance 1 (R1) 1.49 1.48 1.49 1.49 1.51
Pivot Point 1.46 1.46 1.47 1.47 1.46
Support 1 (S1) 1.45 1.45 1.46 1.45 1.43
Support 2 (S2) 1.42 1.44 1.43 1.42
Support 3 (S3) 1.41 1.42 1.42
Support 4 (S4) 1.41